Ontology type: schema:ScholarlyArticle
2004-10
AUTHORSWolf Köster, G. Stamatis, A. Heider, K. Avramidis, H. Wilke, J.A. Koch, M. Stahl
ABSTRACTBackground and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin’s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).Patients and methods: Carboplatin was administered as a 1-hour infusion on day 1 at increasing dose levels, and bendamustine was administered as a short infusion on days 1 and 2 at increasing dose levels (80–120 mg/m2). The regimen was administered every 3 weeks. Four dose levels were planned, starting with 80 mg/m2 bendamustine and carboplatin area under the curve (AUC) 5 (dose level I). The other dose levels were 100 mg/m2 bendamustine and carboplatin AUC 5 (dose level II), 100 mg/m2 bendamustine and carboplatin AUC 6 (dose level III), and 120 mg/m2 bendamustine and carboplatin AUC 6 (dose level IV). A minimum of three patients were enrolled at each dose level.Results: Dose-limiting toxicities, which included fatigue, infection and tachyarrhythmia, were observed at dose level III. The recommended dose for phase II studies was therefore established at dose level II. The majority of haematological and non-haematological toxicities observed were only mild (grade 1 or 2) in patients at dose levels I and II. None of the patients developed severe alopecia. Objective responses were observed in eight of the ten patients involved in this trial.Conclusion: Because of its acceptable toxicity and favourable preliminary antitumour efficacy, the combination of carboplatin and bendamustine appears to be a potentially useful chemotherapeutic option in patients with extensive SCLC. More... »
PAGES611-618
http://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007
DOIhttp://dx.doi.org/10.2165/00044011-200424100-00007
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1052951906
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/17523723
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany",
"id": "http://www.grid.ac/institutes/grid.461714.1",
"name": [
"Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
],
"type": "Organization"
},
"familyName": "K\u00f6ster",
"givenName": "Wolf",
"id": "sg:person.0742143752.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742143752.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Ruhrlandklinik Essen, Essen, Germany",
"id": "http://www.grid.ac/institutes/grid.477805.9",
"name": [
"Ruhrlandklinik Essen, Essen, Germany"
],
"type": "Organization"
},
"familyName": "Stamatis",
"givenName": "G.",
"id": "sg:person.0743515207.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743515207.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Klinikum Leverkusen, Leverkusen, Germany",
"id": "http://www.grid.ac/institutes/grid.419829.f",
"name": [
"Klinikum Leverkusen, Leverkusen, Germany"
],
"type": "Organization"
},
"familyName": "Heider",
"givenName": "A.",
"id": "sg:person.01056372352.21",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056372352.21"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany",
"id": "http://www.grid.ac/institutes/grid.461714.1",
"name": [
"Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
],
"type": "Organization"
},
"familyName": "Avramidis",
"givenName": "K.",
"id": "sg:person.01124505552.23",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124505552.23"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany",
"id": "http://www.grid.ac/institutes/grid.461714.1",
"name": [
"Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
],
"type": "Organization"
},
"familyName": "Wilke",
"givenName": "H.",
"id": "sg:person.011000603017.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011000603017.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany",
"id": "http://www.grid.ac/institutes/grid.461714.1",
"name": [
"Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
],
"type": "Organization"
},
"familyName": "Koch",
"givenName": "J.A.",
"id": "sg:person.01230075746.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230075746.29"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany",
"id": "http://www.grid.ac/institutes/grid.461714.1",
"name": [
"Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik f\u00fcr Innere Medizin I und IV, Internistische Onkologie/H\u00e4matologie, Zentrum f\u00fcr Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany"
],
"type": "Organization"
},
"familyName": "Stahl",
"givenName": "M.",
"id": "sg:person.0616031606.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616031606.75"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s007610050290",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048745128",
"https://doi.org/10.1007/s007610050290"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s004320050225",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045393304",
"https://doi.org/10.1007/s004320050225"
],
"type": "CreativeWork"
}
],
"datePublished": "2004-10",
"datePublishedReg": "2004-10-01",
"description": "Background and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin\u2019s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).Patients and methods: Carboplatin was administered as a 1-hour infusion on day 1 at increasing dose levels, and bendamustine was administered as a short infusion on days 1 and 2 at increasing dose levels (80\u2013120 mg/m2). The regimen was administered every 3 weeks. Four dose levels were planned, starting with 80 mg/m2 bendamustine and carboplatin area under the curve (AUC) 5 (dose level I). The other dose levels were 100 mg/m2 bendamustine and carboplatin AUC 5 (dose level II), 100 mg/m2 bendamustine and carboplatin AUC 6 (dose level III), and 120 mg/m2 bendamustine and carboplatin AUC 6 (dose level IV). A minimum of three patients were enrolled at each dose level.Results: Dose-limiting toxicities, which included fatigue, infection and tachyarrhythmia, were observed at dose level III. The recommended dose for phase II studies was therefore established at dose level II. The majority of haematological and non-haematological toxicities observed were only mild (grade 1 or 2) in patients at dose levels I and II. None of the patients developed severe alopecia. Objective responses were observed in eight of the ten patients involved in this trial.Conclusion: Because of its acceptable toxicity and favourable preliminary antitumour efficacy, the combination of carboplatin and bendamustine appears to be a potentially useful chemotherapeutic option in patients with extensive SCLC.",
"genre": "article",
"id": "sg:pub.10.2165/00044011-200424100-00007",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1100199",
"issn": [
"1173-2563",
"1179-1918"
],
"name": "Clinical Drug Investigation",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "10",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "24"
}
],
"keywords": [
"small cell lung cancer",
"extensive-stage small-cell lung cancer",
"cell lung cancer",
"m2 bendamustine",
"dose levels",
"AUC 6",
"untreated patients",
"lung cancer",
"day 1",
"extensive small cell lung cancer",
"dose level III",
"dose level II",
"non-haematological toxicity",
"phase II study",
"combination of carboplatin",
"dose level I",
"dose-finding study",
"subjective remission",
"AUC 5",
"carboplatin area",
"II study",
"objective response",
"acceptable toxicity",
"Hodgkin's lymphoma",
"multiple myeloma",
"short infusion",
"chemotherapeutic options",
"antitumour efficacy",
"severe alopecia",
"bendamustine",
"curve 5",
"side effects",
"Level I",
"patients",
"solid tumors",
"level III",
"level II",
"carboplatin",
"high efficacy",
"dose",
"lymphoma",
"infusion",
"lower rates",
"cancer",
"efficacy",
"toxicity",
"monotherapy",
"remission",
"regimen",
"tachyarrhythmias",
"levels",
"myeloma",
"alopecia",
"tumors",
"infection",
"trials",
"weeks",
"study",
"options",
"majority",
"agents",
"fatigue",
"response",
"combination",
"background",
"rate",
"effect",
"objective",
"area",
"method",
"minimum",
"maximum"
],
"name": "Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)",
"pagination": "611-618",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1052951906"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.2165/00044011-200424100-00007"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"17523723"
]
}
],
"sameAs": [
"https://doi.org/10.2165/00044011-200424100-00007",
"https://app.dimensions.ai/details/publication/pub.1052951906"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-20T07:22",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_391.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.2165/00044011-200424100-00007"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00044011-200424100-00007'
This table displays all metadata directly associated to this object as RDF triples.
190 TRIPLES
22 PREDICATES
101 URIs
91 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.2165/00044011-200424100-00007 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1112 |
3 | ″ | schema:author | Nca81e337d2f54ffc8c3d4b6e0ee2af06 |
4 | ″ | schema:citation | sg:pub.10.1007/s004320050225 |
5 | ″ | ″ | sg:pub.10.1007/s007610050290 |
6 | ″ | schema:datePublished | 2004-10 |
7 | ″ | schema:datePublishedReg | 2004-10-01 |
8 | ″ | schema:description | Background and objective: Bendamustine is an alkylating agent with high efficacy in non-Hodgkin’s lymphoma and multiple myeloma. Even in solid tumours, monotherapy with bendamustine has resulted in subjective remissions and has been associated with a low rate of side effects. The current dose-finding study was designed to determine the maximum tolerated dose (MTD) of combined carboplatin/bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC).Patients and methods: Carboplatin was administered as a 1-hour infusion on day 1 at increasing dose levels, and bendamustine was administered as a short infusion on days 1 and 2 at increasing dose levels (80–120 mg/m2). The regimen was administered every 3 weeks. Four dose levels were planned, starting with 80 mg/m2 bendamustine and carboplatin area under the curve (AUC) 5 (dose level I). The other dose levels were 100 mg/m2 bendamustine and carboplatin AUC 5 (dose level II), 100 mg/m2 bendamustine and carboplatin AUC 6 (dose level III), and 120 mg/m2 bendamustine and carboplatin AUC 6 (dose level IV). A minimum of three patients were enrolled at each dose level.Results: Dose-limiting toxicities, which included fatigue, infection and tachyarrhythmia, were observed at dose level III. The recommended dose for phase II studies was therefore established at dose level II. The majority of haematological and non-haematological toxicities observed were only mild (grade 1 or 2) in patients at dose levels I and II. None of the patients developed severe alopecia. Objective responses were observed in eight of the ten patients involved in this trial.Conclusion: Because of its acceptable toxicity and favourable preliminary antitumour efficacy, the combination of carboplatin and bendamustine appears to be a potentially useful chemotherapeutic option in patients with extensive SCLC. |
9 | ″ | schema:genre | article |
10 | ″ | schema:inLanguage | en |
11 | ″ | schema:isAccessibleForFree | false |
12 | ″ | schema:isPartOf | N64695fa9831b4c4a8bf226a338b03503 |
13 | ″ | ″ | Ndc473d21f38f4f9bb00948a7aaaa3607 |
14 | ″ | ″ | sg:journal.1100199 |
15 | ″ | schema:keywords | AUC 5 |
16 | ″ | ″ | AUC 6 |
17 | ″ | ″ | Hodgkin's lymphoma |
18 | ″ | ″ | II study |
19 | ″ | ″ | Level I |
20 | ″ | ″ | acceptable toxicity |
21 | ″ | ″ | agents |
22 | ″ | ″ | alopecia |
23 | ″ | ″ | antitumour efficacy |
24 | ″ | ″ | area |
25 | ″ | ″ | background |
26 | ″ | ″ | bendamustine |
27 | ″ | ″ | cancer |
28 | ″ | ″ | carboplatin |
29 | ″ | ″ | carboplatin area |
30 | ″ | ″ | cell lung cancer |
31 | ″ | ″ | chemotherapeutic options |
32 | ″ | ″ | combination |
33 | ″ | ″ | combination of carboplatin |
34 | ″ | ″ | curve 5 |
35 | ″ | ″ | day 1 |
36 | ″ | ″ | dose |
37 | ″ | ″ | dose level I |
38 | ″ | ″ | dose level II |
39 | ″ | ″ | dose level III |
40 | ″ | ″ | dose levels |
41 | ″ | ″ | dose-finding study |
42 | ″ | ″ | effect |
43 | ″ | ″ | efficacy |
44 | ″ | ″ | extensive small cell lung cancer |
45 | ″ | ″ | extensive-stage small-cell lung cancer |
46 | ″ | ″ | fatigue |
47 | ″ | ″ | high efficacy |
48 | ″ | ″ | infection |
49 | ″ | ″ | infusion |
50 | ″ | ″ | level II |
51 | ″ | ″ | level III |
52 | ″ | ″ | levels |
53 | ″ | ″ | lower rates |
54 | ″ | ″ | lung cancer |
55 | ″ | ″ | lymphoma |
56 | ″ | ″ | m2 bendamustine |
57 | ″ | ″ | majority |
58 | ″ | ″ | maximum |
59 | ″ | ″ | method |
60 | ″ | ″ | minimum |
61 | ″ | ″ | monotherapy |
62 | ″ | ″ | multiple myeloma |
63 | ″ | ″ | myeloma |
64 | ″ | ″ | non-haematological toxicity |
65 | ″ | ″ | objective |
66 | ″ | ″ | objective response |
67 | ″ | ″ | options |
68 | ″ | ″ | patients |
69 | ″ | ″ | phase II study |
70 | ″ | ″ | rate |
71 | ″ | ″ | regimen |
72 | ″ | ″ | remission |
73 | ″ | ″ | response |
74 | ″ | ″ | severe alopecia |
75 | ″ | ″ | short infusion |
76 | ″ | ″ | side effects |
77 | ″ | ″ | small cell lung cancer |
78 | ″ | ″ | solid tumors |
79 | ″ | ″ | study |
80 | ″ | ″ | subjective remission |
81 | ″ | ″ | tachyarrhythmias |
82 | ″ | ″ | toxicity |
83 | ″ | ″ | trials |
84 | ″ | ″ | tumors |
85 | ″ | ″ | untreated patients |
86 | ″ | ″ | weeks |
87 | ″ | schema:name | Carboplatin in Combination with Bendamustine in Previously Untreated Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) |
88 | ″ | schema:pagination | 611-618 |
89 | ″ | schema:productId | N275e468215aa4bde91be6578c71c2323 |
90 | ″ | ″ | N3fb6b4f5ca3f4f5d8d3d767c5dfa17a0 |
91 | ″ | ″ | N6bf098e11d8d420fb5abec8825016518 |
92 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1052951906 |
93 | ″ | ″ | https://doi.org/10.2165/00044011-200424100-00007 |
94 | ″ | schema:sdDatePublished | 2022-05-20T07:22 |
95 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
96 | ″ | schema:sdPublisher | Na235b04104e349269500d9e2703748fd |
97 | ″ | schema:url | https://doi.org/10.2165/00044011-200424100-00007 |
98 | ″ | sgo:license | sg:explorer/license/ |
99 | ″ | sgo:sdDataset | articles |
100 | ″ | rdf:type | schema:ScholarlyArticle |
101 | N275e468215aa4bde91be6578c71c2323 | schema:name | dimensions_id |
102 | ″ | schema:value | pub.1052951906 |
103 | ″ | rdf:type | schema:PropertyValue |
104 | N2c65f4ee938a4eccb6b7f7ebabc11f85 | rdf:first | sg:person.011000603017.19 |
105 | ″ | rdf:rest | Na5a87839db694cc1bb29febce2caef35 |
106 | N397bbaa1bf284291ae1d43ca6c5fcaf9 | rdf:first | sg:person.0743515207.27 |
107 | ″ | rdf:rest | Nfd5480febbbd4820ab21cfe09af0e42d |
108 | N3fb6b4f5ca3f4f5d8d3d767c5dfa17a0 | schema:name | doi |
109 | ″ | schema:value | 10.2165/00044011-200424100-00007 |
110 | ″ | rdf:type | schema:PropertyValue |
111 | N64695fa9831b4c4a8bf226a338b03503 | schema:issueNumber | 10 |
112 | ″ | rdf:type | schema:PublicationIssue |
113 | N67437200b25f4f2a842687f1588f87ca | rdf:first | sg:person.01124505552.23 |
114 | ″ | rdf:rest | N2c65f4ee938a4eccb6b7f7ebabc11f85 |
115 | N6bf098e11d8d420fb5abec8825016518 | schema:name | pubmed_id |
116 | ″ | schema:value | 17523723 |
117 | ″ | rdf:type | schema:PropertyValue |
118 | Na235b04104e349269500d9e2703748fd | schema:name | Springer Nature - SN SciGraph project |
119 | ″ | rdf:type | schema:Organization |
120 | Na5a87839db694cc1bb29febce2caef35 | rdf:first | sg:person.01230075746.29 |
121 | ″ | rdf:rest | Nd8cf8fd430a94287b464230763ef0cdc |
122 | Nca81e337d2f54ffc8c3d4b6e0ee2af06 | rdf:first | sg:person.0742143752.53 |
123 | ″ | rdf:rest | N397bbaa1bf284291ae1d43ca6c5fcaf9 |
124 | Nd8cf8fd430a94287b464230763ef0cdc | rdf:first | sg:person.0616031606.75 |
125 | ″ | rdf:rest | rdf:nil |
126 | Ndc473d21f38f4f9bb00948a7aaaa3607 | schema:volumeNumber | 24 |
127 | ″ | rdf:type | schema:PublicationVolume |
128 | Nfd5480febbbd4820ab21cfe09af0e42d | rdf:first | sg:person.01056372352.21 |
129 | ″ | rdf:rest | N67437200b25f4f2a842687f1588f87ca |
130 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
131 | ″ | schema:name | Medical and Health Sciences |
132 | ″ | rdf:type | schema:DefinedTerm |
133 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
134 | ″ | schema:name | Oncology and Carcinogenesis |
135 | ″ | rdf:type | schema:DefinedTerm |
136 | sg:journal.1100199 | schema:issn | 1173-2563 |
137 | ″ | ″ | 1179-1918 |
138 | ″ | schema:name | Clinical Drug Investigation |
139 | ″ | schema:publisher | Springer Nature |
140 | ″ | rdf:type | schema:Periodical |
141 | sg:person.01056372352.21 | schema:affiliation | grid-institutes:grid.419829.f |
142 | ″ | schema:familyName | Heider |
143 | ″ | schema:givenName | A. |
144 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056372352.21 |
145 | ″ | rdf:type | schema:Person |
146 | sg:person.011000603017.19 | schema:affiliation | grid-institutes:grid.461714.1 |
147 | ″ | schema:familyName | Wilke |
148 | ″ | schema:givenName | H. |
149 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011000603017.19 |
150 | ″ | rdf:type | schema:Person |
151 | sg:person.01124505552.23 | schema:affiliation | grid-institutes:grid.461714.1 |
152 | ″ | schema:familyName | Avramidis |
153 | ″ | schema:givenName | K. |
154 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124505552.23 |
155 | ″ | rdf:type | schema:Person |
156 | sg:person.01230075746.29 | schema:affiliation | grid-institutes:grid.461714.1 |
157 | ″ | schema:familyName | Koch |
158 | ″ | schema:givenName | J.A. |
159 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230075746.29 |
160 | ″ | rdf:type | schema:Person |
161 | sg:person.0616031606.75 | schema:affiliation | grid-institutes:grid.461714.1 |
162 | ″ | schema:familyName | Stahl |
163 | ″ | schema:givenName | M. |
164 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616031606.75 |
165 | ″ | rdf:type | schema:Person |
166 | sg:person.0742143752.53 | schema:affiliation | grid-institutes:grid.461714.1 |
167 | ″ | schema:familyName | Köster |
168 | ″ | schema:givenName | Wolf |
169 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742143752.53 |
170 | ″ | rdf:type | schema:Person |
171 | sg:person.0743515207.27 | schema:affiliation | grid-institutes:grid.477805.9 |
172 | ″ | schema:familyName | Stamatis |
173 | ″ | schema:givenName | G. |
174 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743515207.27 |
175 | ″ | rdf:type | schema:Person |
176 | sg:pub.10.1007/s004320050225 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1045393304 |
177 | ″ | ″ | https://doi.org/10.1007/s004320050225 |
178 | ″ | rdf:type | schema:CreativeWork |
179 | sg:pub.10.1007/s007610050290 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1048745128 |
180 | ″ | ″ | https://doi.org/10.1007/s007610050290 |
181 | ″ | rdf:type | schema:CreativeWork |
182 | grid-institutes:grid.419829.f | schema:alternateName | Klinikum Leverkusen, Leverkusen, Germany |
183 | ″ | schema:name | Klinikum Leverkusen, Leverkusen, Germany |
184 | ″ | rdf:type | schema:Organization |
185 | grid-institutes:grid.461714.1 | schema:alternateName | Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik für Innere Medizin I und IV, Internistische Onkologie/Hämatologie, Zentrum für Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany |
186 | ″ | schema:name | Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Klinik für Innere Medizin I und IV, Internistische Onkologie/Hämatologie, Zentrum für Palliativmedizin, Henricistrasse 92, D-45136, Essen, Germany |
187 | ″ | rdf:type | schema:Organization |
188 | grid-institutes:grid.477805.9 | schema:alternateName | Ruhrlandklinik Essen, Essen, Germany |
189 | ″ | schema:name | Ruhrlandklinik Essen, Essen, Germany |
190 | ″ | rdf:type | schema:Organization |